AIM ImmunoTech Inc. (AIMI)
OTCMKTS
· Delayed Price · Currency is USD
0.0999
-0.0001 (-0.10%)
May 12, 2025, 9:30 AM EDT
AIM ImmunoTech Revenue
In the year 2024, AIM ImmunoTech had annual revenue of $170.00K, down -15.84%. AIM ImmunoTech had revenue of $45.00K in the quarter ending December 31, 2024, a decrease of -30.77%.
Revenue
170.00K
Revenue Growth
-15.84%
P/S Ratio
44.65
Revenue / Employee
7.73K
Employees
23
Market Cap
7.59M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 170.00K | -32.00K | -15.84% |
Dec 31, 2023 | 202.00K | 61.00K | 43.26% |
Dec 31, 2022 | 141.00K | 6.00K | 4.44% |
Dec 31, 2021 | 135.00K | -28.00K | -17.18% |
Dec 31, 2020 | 163.00K | 23.00K | 16.43% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
AIM ImmunoTech News
- 5 days ago - AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists - GlobeNewsWire
- 5 weeks ago - AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market - GlobeNewsWire
- 5 weeks ago - AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - GlobeNewsWire
- 5 weeks ago - NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM) - Business Wire
- 6 weeks ago - AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire
- 2 months ago - AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza - GlobeNewsWire